Mirum Pharmaceuticals’ Phase 3 EXPAND Meets Primary Endpoint
Mirum Pharmaceuticals said LIVMARLI met the primary endpoint and key secondary endpoints in the Phase 3 EXPAND trial for cholestatic pruritus. The company plans to submit a U.S. supplemental NDA in the first half of 2027.